In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder

Journal of Neural Transmission

Volumn 120, Issue 1, 2013, Pages 131-139

  Grünblatt, Edna ^a,b   Bartl, Jasmin ^b   Marinova, Zoya ^a   Walitza, Susanne ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Cell culture; Electrophysiology; Methylphenidate; Neuron

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE;

ASTROCYTE; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BRAIN ELECTROPHYSIOLOGY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DNA POLYMORPHISM; DRUG BINDING; DRUG EFFECT; DRUG TRANSPORT; GENE CONSTRUCT; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GLIA CELL; HEREDITY; HERITABILITY; HUMAN; IN VITRO STUDY; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; NORETHANDROLONE; POLYMORPHISM, GENETIC; TRANSFECTION;

EID: 84872316775     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0869-9     Document Type: Review

References (61)

1. Andrews GD, Lavin A (2006) Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology 31:594-601 (Pubitemid 43276975)
2. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2008) Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations. Z Kinder Jugendpsychiatr Psychother 36:81-94; quiz 94-95
3. Bartl J, Link P, Schlosser C, Gerlach M, Schmitt A, Walitza S, Riederer P, Grünblatt E (2011) Effects of methylphenidate: the cellular point of view. Atten Defic Hyperact Disord 2:225-232
4. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, Han Y, Sen N, Urizar E, Gomes I, Devi LA, Ramamoorthy S, Javitch JA, Zapata A, Shippenberg TS (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 71:1222-1232 (Pubitemid 46661542)
5. Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, Jessen T, Colbran RJ, Caron MG, Javitch JA, Blakely RD, Galli A (2010) Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 30:6048-6057
6. Challman TD, Lipsky JJ (2000) Methylphenidate: its pharmacology and uses. Mayo Clin Proc 75:711-721 (Pubitemid 30441501)
7. Chamberlain C, Hahn KM (2000) Watching proteins in the wild: fluorescence methods to study protein dynamics in living cells. Traffic 1:755-762
8. Daws LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121:89-99
9. Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A (2009) Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 23:739-753
10. Diemert S, Dolga AM, Tobaben S, Grohm J, Pfeifer S, Oexler E, Culmsee C (2012) Impedance measurement for real time detection of neuronal cell death. J Neurosci Methods 203:69-77
11. Faraone SV, Doyle AE (2001) The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 10:299-316, viii-ix (Pubitemid 32416828)
12. Garini Y, Vermolen BJ, Young IT (2005) From micro to nano: recent advances in high-resolution microscopy. Curr Opin Biotechnol 16:3-12 (Pubitemid 40253578)
13. Giepmans BN, Adams SR, Ellisman MH, Tsien RY (2006) The fluorescent toolbox for assessing protein location and function. Science 312:217-224
14. Graham J et al (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17-37
15. Hell SW (2009) Microscopy and its focal switch. Nat Methods 6:24-32
16. Hildick KL, González-González IM, Jaskolski F, Henley JM (2012) Lateral diffusion and exocytosis of membrane proteins in cultured neurons assessed using fluorescence recovery and fluorescence-loss photobleaching. J Vis Exp, pii: 3747
17. Hinojosa-Arango G, Maggs CA, Johnson MP (2009) Like a rolling stone: the mobility of maerl (Corallinaceae) and the neutrality of the associated assemblages. Ecology 90:517-528
18. Ishimatsu M, Kidani Y, Tsuda A, Akasu T (2002) Effects of methylphenidate on the membrane potential and current in neurons of the rat locus coeruleus. J Neurophysiol 87:1206-1212 (Pubitemid 34670787)
19. Jacob CP, Romanos J, Dempfle A, Heine M, Windemuth-Kieselbach C, Kruse A, Reif A, Walitza S, Romanos M, Strobel A, Brocke B, Schafer H, Schmidtke A, Boning J, Lesch KP (2007) Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci 257:309-317 (Pubitemid 47476717)
20. Kakazu Y, Koh JY, Ho KW, Gonzalez-Alegre P, Harata NC (2012) Synaptic vesicle recycling is enhanced by torsinA that harbors the DYT1 dystonia mutation. Synapse 66:453-464
21. Kidani Y, Ishimatsu M, Akasu T (2010) Methylphenidate enhances inhibitory synaptic transmission by increasing the content of norepinephrine in the locus coeruleus of juvenile rats. Kurume Med J 57:29-38
22. + channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine. Neuropsychopharmacology 35:1560-1569
23. Kotaleski JH, Blackwell KT (2010) Modelling the molecular mechanisms of synaptic plasticity using systems biology approaches. Nat Rev Neurosci 11:239-251
24. Lippincott-Schwartz J, Patterson GH (2003) Development and use of fluorescent protein markers in living cells. Science 300:87-91 (Pubitemid 36423032)
25. Loder MK, Melikian HE (2003) The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 278:22168-22174 (Pubitemid 36792628)
26. Ludolph AG, Schaz U, Storch A, Liebau S, Fegert JM, Boeckers TM (2006) Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J Neural Transm 113:1927-1934 (Pubitemid 44749635)
27. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Fohr KJ (2010) Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol 160:283-291
28. Markowitz JS, Patrick KS (2008) Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 28:S54-S61
29. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16:687-698 (Pubitemid 46175425)
30. Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ (2009) The psychostimulant d-threo-(R, R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Pharmazie 64:123-125
31. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100:2430-2436 (Pubitemid 27514881)
32. Meijering E, Dzyubachyk O, Smal I, van Cappellen WA (2009) Tracking in cell and developmental biology. Semin Cell Dev Biol 20:894-902
33. Miyatake M, Narita M, Shibasaki M, Nakamura A, Suzuki T (2005) Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur J Neurosci 22:1476-1488 (Pubitemid 41442419)
34. Narita M, Miyatake M, Shibasaki M, Tsuda M, Koizumi S, Yajima Y, Inoue K, Suzuki T (2005) Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. J Neurochem 93:1383-1392 (Pubitemid 40853261)
35. Narita M, Miyatake M, Shibasaki M, Shindo K, Nakamura A, Kuzumaki N, Nagumo Y, Suzuki T (2006) Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 31:2476-2488 (Pubitemid 44607065)
36. Narita M, Asato M, Shindo K, Kuzumaki N, Suzuki T (2009) Differences in neuronal toxicity and its molecular mechanisms between methamphetamine and methylphenidate. Nihon Shinkei Seishin Yakurigaku Zasshi 29:115-120
37. Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M (2009) Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 57:731-733
38. Nemoda Z, Szekely A, Sasvari-Szekely M (2011) Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood. Neurosci Biobehav Rev 35:1665-1686
39. Oz M, Libby T, Kivell B, Jaligam V, Ramamoorthy S, Shippenberg TS (2010) Real-time, spatially resolved analysis of serotonin transporter activity and regulation using the fluorescent substrate, ASP+. J Neurochem 114:1019-1029
40. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942-948 (Pubitemid 46972911)
41. Prieto-Gomez B, Benitez MT, Vazquez-Alvarez AM, Yang PB, Reyes Vazquez C, Dafny N (2004) Dopaminergic ventral tegmental neurons modulated by methylphenidate. Life Sci 74:1581-1592 (Pubitemid 38114790)
42. Prieto-Gomez B, Vazquez-Alvarez AM, Martinez-Pena JL, Reyes-Vazquez C, Yang PB, Dafny N (2005) Methylphenidate and amphetamine modulate differently the NMDA and AMPA glutamatergic transmission of dopaminergic neurons in the ventral tegmental area. Life Sci 77:635-649 (Pubitemid 40726351)
43. Purper-Ouakil D, Ramoz N, Lepagnol-Bestel AM, Gorwood P, Simonneau M (2011) Neurobiology of attention deficit/hyperactivity disorder. Pediatr Res 69:69R-76R
44. Schmidt AJ, Krieg JC, Clement HW, Gebhardt S, Schulz E, Heiser P (2010a) Impact of drugs approved for treating ADHD on the cell survival and energy metabolism: an in vitro study in human neuronal and immune cells. J Psychopharmacol 24:1829-1833
45. Schmidt AJ, Clement HW, Gebhardt S, Hemmeter UM, Schulz E, Krieg JC, Kircher T, Heiser P (2010b) Impact of psychostimulants and atomoxetine on the expression of 8-hydroxyguanine glycosylase 1 in human cells. J Neural Transm 117:793-797
46. Stephens DJ, Allan VJ (2003) Light microscopy techniques for live cell imaging. Science 300:82-86 (Pubitemid 36423031)
47. Suzuki T, Shindo K, Miyatake M, Kurokawa K, Higashiyama K, Suzuki M, Narita M (2007) Lack of development of behavioral sensitization to methylphenidate in mice: correlation with reversible astrocytic activation. Eur J Pharmacol 574:39-48 (Pubitemid 47503161)
48. Tsien RY (2003) Imagining imaging's future. Nat Rev Mol Cell Biol Suppl:SS16-SS21 (Pubitemid 37082172)
49. Ukairo OT, Ramanujapuram S, Surratt CK (2007) Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter. Brain Res 1131:68-76 (Pubitemid 46070178)
50. Vaccarino FM, Urban AE, Stevens HE, Szekely A, Abyzov A, Grigorenko EL, Gerstein M, Weissman S (2011) Annual research review: the promise of stem cell research for neuropsychiatric disorders. J Child Psychol Psychiatry 52:504-516
51. van Asperen J, Mayer U, van Tellingen O, Beijnen JH (1997) The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86:881-884 (Pubitemid 27344043)
52. Vandenbergh DJ, Persico AM, Uhl GR (1992a) A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res 15:161-166
53. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (1992b) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106 (Pubitemid 23053054)
54. VanNess SH, Owens MJ, Kilts CD (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6:55 (Pubitemid 41762656)
55. Xiao C, Lachance B, Sunahara G, Luong JH (2002) Assessment of cytotoxicity using electric cell-substrate impedance sensing: concentration and time response function approach. Anal Chem 74:5748-5753 (Pubitemid 35364829)
56. Yamagata K (2010) DNA methylation profiling using live-cell imaging. Methods 52:259-266
57. Yatin SM, Miller GM, Norton C, Madras BK (2002) Dopamine transporter-dependent induction of C-Fos in HEK cells. Synapse 45:52-65 (Pubitemid 34595064)
58. Yatin SM, Miller GM, Madras BK (2005) Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation. J Neurosci Methods 143:69-78 (Pubitemid 40352536)
59. Zhang L, Chang S, Li Z, Zhang K, Du Y, Ott J, Wang J (2012) ADHDgene: a genetic database for attention deficit hyperactivity disorder. Nucl Acids Res 40:D1003-D1009
60. Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS (2008a) Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. Eur J Pharmacol 578:148-158 (Pubitemid 350309594)
61. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS (2008b) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241-1248